DUBLIN, March 27, 2018 /PRNewswire/ --
The "Neurofibromatosis Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" report has been added to ResearchAndMarkets.com's offering.
The study analyzed that the Neurofibromatosis therapeutics pipeline comprises of approximately 25 therapeutic candidates in different stages of development.
Majority of the pipeline drug candidates are being developed to be administered by oral route. Celldex Therapeutics Inc. and Merck Co. Inc. are in the process of developing a monoclonal antibody drug candidate, CDX0158, and Pembrolizumab respectively for the treatment of NF. Lixte Biotechnology Holdings Inc. is in the process of developing two drug candidates, in the Pre-Clinical stage of development for the treatment of neurofibromatosis (NF). In September 2016, the USFDA granted Orphan Drug Designation to BXCL101, a drug candidate of BioXcel Therapeutics Inc. for the treatment of NF type 2.
Unmet medical needs driving the neurofibromatosis therapeutics pipeline
Since there is no treatment available for NF, the growing medical needs of the people suffering from the disease are driving its therapeutics pipeline growth. High rate of recurrence/progression of the disease and poor long-term benefit of surgery can be viewed as a limitation of this treatment option.
Positive clinical trial results propelling the growth of the pipeline therapeutics of the Neurofibromatosis
The drugs being developed by the different pharmaceutical companies demonstrated positive clinical trial results which in-turn increasing their further development. For instance, In June 2014, Array BioPharma Inc. announced positive results of Phase I/II, combination of binimetinib and LEE011. Selumetinib being developed by the AstraZeneca plc. And it met primary endpoint as confirmed partial responses (tumor volume decreases from baseline of =20%) in 17 of the 24 children (71%) in Phase I study.
Some of the key players developing drugs for the treatment of neurofibromatosis include Novartis AG, AstraZeneca Plc, Pfizer Inc., GlaxoSmithKline plc, Merck & Co. Inc, BioXcel Therapeutics, Inc.
Key Topics Covered:
1. Research Background
1.1 Research Objectives
1.3 Research Scope
1.3.1 Pipeline Analysis by Phase
1.3.2 Pipeline Analysis by Molecule Type
1.3.3 Pipeline Analysis by Route of Administration
1.4 Key Stakeholders
2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents
188.8.131.52 by industry participant
184.108.40.206 by company type
3. Executive Summary
4. Pipeline Outlook
4.1 Disease Overview
4.1.1 Types of Neurofibromatosis
4.2 Causes and Symptoms
4.3.1 NF1 Diagnosis
4.3.2 NF2 Diagnosis
4.8 Key Drivers
4.9 Key Barriers
4.9.1 Overlapping of NF with Many RAS-Driven Disorders
4.10 Neurofibromatosis Therapeutics Pipeline Analysis
4.10.1 Pipeline Analysis by Phase
4.10.2 Pipeline Analysis by Molecule Type
4.10.3 Pipeline Analysis by Route of Administration
4.10.4 Pipeline Analysis by Company
5. Neurofibromatosis (NF) Therapeutics Pipeline Analysis by Phase (2018)
5.1 Phase II
220.127.116.11 Clinical trial
18.104.22.168 Clinical trial results
22.214.171.124 Strategic development
126.96.36.199 Clinical trial
188.8.131.52 Clinical trial results
5.2 Phase I/II
5.3 Phase 0
184.108.40.206 Clinical trials
220.127.116.11 Strategic development
18.104.22.168 Strategic development
5.5.1 Small Molecule to Inhibit Hsp90-Alpha and TRAP1 for NF Type 2
22.214.171.124 Strategic development
6. Clinical Trials Review
6.1 Clinical Trials by Region
6.2 Clinical Trials by Trial Status
7. Competitive Landscape
7.1 Key Players Benchmarking for NF Therapeutics Pipeline
7.2 SWOT Analysis of Neurofibromatosis Therapeutics Pipeline
8. Company Profiles
- Array Biopharma Inc.
- Recursion Pharmaceuticals Inc.
- Celldex Therapeutics Inc.
- Merck Co
- Novartis AG
- AstraZeneca Plc
- Pfizer Inc.
- GlaxoSmithKline plc
- BioXcel Therapeutics, Inc.
For more information about this report visit https://www.researchandmarkets.com/research/6tc3wz/neurofibromatosis?w=5
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets